Sweden’s AP1 and AP4 to Invest in Domestic Cancer Treatment Firm

Posted on 12/07/2017


Swedish national pension buffer funds AP1 and AP4 intend on investing in Cantargia AB, a domestic biotechnology firm that is seeking to develop an antibody-based treatment for a number of forms of cancer. Cantargia is raising new capital for its research through a 101 million SEK (US$ 11.99 million) directed share issue for non-shareholders, and […]